---
title: "Regeneron Q2 Adjusted EPS USD 14.29 Vs. IBES Estimate USD 10.3"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294345176.md"
datetime: "2026-07-30T10:31:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294345176.md)
  - [en](https://longbridge.com/en/news/294345176.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294345176.md)
---

# Regeneron Q2 Adjusted EPS USD 14.29 Vs. IBES Estimate USD 10.3

Jul 30 (Reuters) - Regeneron Q2 revenue USD 4,291 million vs. IBES estimate USD 3,816 million. \* Q2 EPS USD 12.23 \* outlook FY capex USD 1,030-1,100 million

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [NewEdge Advisors LLC Has $5.88 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/295508474.md)
- [12:37 ETREGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit](https://longbridge.com/en/news/294851069.md)
- [CTMX: Varseta-M advances in CRC and GI cancers, supported by strong cash and expanded Regeneron collaboration](https://longbridge.com/en/news/295154296.md)
- [Biocon launches Yesafili biosimilar to Regeneron’s Eylea in US](https://longbridge.com/en/news/294636157.md)
- [10:19 ETWhite Rocks Amphitheater and UMusic Hotel & Private Residences to Create Permanent Arts Endowment](https://longbridge.com/en/news/295550392.md)